Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 119

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 119
---
 costs in meeting demand in the event we must switch to a new supplier. The time and effort required to qualify a new supplier could result in additional results. Accordingly, we may not be able to establish or maintain reliable, high -volumemanufacturing at commercially reasonable costs. In addition, the manufacture or shipment of our products may be delayed or interrupted if the quality of the products, sub -assemblies, components, or materials supplied by our vendors does not meet our requirements. Current or future social and environmental regulations or critical issues could restrict the supply of components and materials used in production or increase our costs. Any delay or interruption to our manufacturing process or in shipping our products could result in lost revenue, which would adversely affect our business, financial condition, or results of operations. In addition, our business depends on our ability to quickly and reliably deliver genetic test results to our customers. We typically receive samples from customers within days of shipment, or in some cases overnight, for genetic sequencing and data analysis at our laboratory facilities. Disruptions in delivery service, whether due to labor disruptions, bad weather or natural disasters (including severe weather, fires or other natural events which may be exacerbated by climate change), pandemics or epidemics, terrorist acts or threats or for other reasons, could adversely affect specimen integrity and our ability to process specimens in a timely manner and otherwise service our customers, and ultimately materially and adversely affect our reputation and our business. In addition, our products incorporate complex computer software which may contain or result in errors or failures, especially when first introduced. In the course of conducting our business, we must adequately address quality issues associated with our products and services, including defects in our engineering and design processes, as well as defects in third -partycomponents included in our products. In addition, new products or enhancements may contain undetected errors or performance problems that, despite testing, are discovered only after commercial shipment. Defects or errors in our test results may discourage customers from purchasing our products. The costs incurred in correcting any defects or errors may affect our reputation substantially and could adversely affect our operating margins. Identifying the root cause of quality issues, particularly those sourced from third parties, may be difficult, which increases the time needed to address quality issues as they arise, and increases the risk that similar 34 problems could recur. As our products are designed to be used to perform complex genomic analysis, we expect that our customers will have an increased sensitivity to such defects. If we do not meet applicable regulatory or quality standards, our services may be